<p>馬薩諸塞州沃爾瑟姆和都柏林，2025 年 12 月 5 日（全球新聞稿）—— Mural Oncology plc（納斯達克：MURA）（“ <strong>Mural</strong>”）宣佈，根據 2014 年公司法第 9 部分第 1 章的安排計劃（“ <strong>計劃</strong>”），XRA 5 Corp.（“ <strong>子公司</strong>”），XOMA Royalty Corporation（納斯達克：XOMA）（“ <strong>XOMA Royalty</strong>”）的全資子公司，將收購 Mural 的全部已發行和待發行股份，計劃於 2025 年 12 月 5 日（“ <strong>生效日期</strong>”）生效。</p>
<p>根據計劃條款，子公司向計劃股東支付的現金對價的支票分發和 DTC 參與者賬户的記賬預計將在生效日期後儘快開始，DTC 參與者賬户預計將被記賬，支票分發預計將盡快完成。根據愛爾蘭收購規則的要求，子公司向計劃股東支付的所有對價將在 2025 年 12 月 19 日之前分發完畢。</p>
<p>Mural 股份在納斯達克全球市場的交易取消自 2025 年 12 月 4 日美國東部時間晚上 8:00 起生效。</p>
<p>除非另有定義，本公告中使用但未定義的專有名詞與 Mural 於 2025 年 9 月 23 日發佈的關於收購的最終代理聲明中所賦予的含義相同，該聲明也構成了根據愛爾蘭法律的計劃通函。</p>
<p>不得在任何法律或法規禁止的司法管轄區內全部或部分發布、出版或分發本公告。</p>
<p>立即發佈</p>
<p><strong>諮詢</strong></p>
<p>Mural Oncology plc</p>
<p>ir@muraloncology.com</p>
<p>Lucid Capital Markets, LLC（Mural 的財務顧問）</p>
<p>570 Lexington Ave, 40 樓</p>
<p>紐約，NY 10022</p>
<p><strong>關於前瞻性聲明的警示説明</strong></p>
<p>本公告中關於非歷史事實事項的聲明為 1995 年私人證券訴訟改革法案所定義的 “前瞻性聲明”，涉及 Mural、XOMA Royalty 或子公司。前瞻性聲明旨在通過 “預期”、“目標”、“期待”、“估計”、“打算”、“計劃”、“相信”、“將”、“可能”、“會”、“可以” 或 “應該” 或其他類似含義的詞語或其否定形式來識別。前瞻性聲明包括但不限於關於子公司向計劃股東支付對價的預計時間以及 Mural 股份在納斯達克全球市場交易取消的預計時間的聲明。</p>
<p>這些前瞻性聲明涉及已知和未知的風險、不確定性及其他因素，可能導致實際結果與這些前瞻性聲明所表達或暗示的結果存在重大差異。可能導致實際結果與預期不同的風險和不確定性包括：與 Mural 業務相關的風險和不確定性，包括在 Mural 最近提交的 10-K 表格年度報告、向美國證券交易委員會（“SEC”）提交的 10-Q 表格季度報告以及 2025 年 9 月 23 日向 SEC 提交的最終代理聲明中所描述的風險和不確定性，以及與 XOMA Royalty 相關的其他潛在風險和不確定性，包括在 XOMA Royalty 最近提交的 10-K 表格年度報告、10-Q 表格季度報告及其其他向 SEC 提交的文件中更詳細描述的風險和不確定性。您被警告不要對這些前瞻性聲明過於依賴，這些聲明僅在作出時有效。所有後續口頭或書面的前瞻性聲明，歸因於 Mural、XOMA Royalty 或子公司或其代表的任何人，均完全受上述警示聲明的限制。Mural、XOMA Royalty 或子公司均不承擔更新或修訂本公告中包含的前瞻性聲明的任何義務，無論是由於新信息、未來事件還是其他原因，除非法律要求。</p>
<p><strong>愛爾蘭收購規則要求的聲明</strong></p>
<p>Mural 的董事會對本公告中包含的信息承擔責任。根據 Mural 董事會的最佳知識和信念（董事會已採取一切合理的注意以確保情況如此），本公告中包含的信息符合事實，並未遺漏任何可能影響該信息重要性的內容。</p>
<p>Lucid 在美國由 SEC 和金融業監管局（“ <strong>FINRA</strong>”）授權和監管，作為 Mural 的財務顧問，僅為 Mural 提供服務，而不為其他任何人提供與本公告主題相關的服務，並且不會將任何其他人視為其在本公告事項中的客户，也不會對除 Mural 以外的任何人提供 Lucid 或其附屬公司的客户所享有的保護，也不會就本公告中提到的任何事項提供建議。Lucid 及其任何子公司、附屬公司或分支機構對任何非 Lucid 客户在本公告中涉及的事項、任何聲明或其他事項或安排不承擔或接受任何責任（無論是直接、間接、後果性，無論是合同、侵權、法定或其他方式）。</p>
<p>Davy Corporate Finance 在愛爾蘭由愛爾蘭中央銀行授權和監管，專門為 XOMA Royalty 提供服務，與本公告中提及的事項相關，不對除 XOMA Royalty 以外的任何人負責提供 Davy Corporate Finance 客户所享有的保護或提供與本公告中提及的事項相關的建議。</p>
<p>Wilmer Cutler Pickering Hale and Dorr LLP 和 Arthur Cox LLP 分別作為 Mural 的美國和愛爾蘭法律顧問，而 Gibson, Dunn &amp; Crutcher LLP 和 Mason Hayes &amp; Curran LLP 則分別作為 XOMA Royalty 和 Sub 的美國和愛爾蘭法律顧問。</p>
<p><strong>一般信息</strong></p>
<p>本公告的發佈、公佈或分發在某些司法管轄區可能受到該等司法管轄區法律的限制。因此，本公告及與收購相關的所有其他文件的副本不得在任何此類受限司法管轄區內或向其發佈、公佈、郵寄或以其他方式轉發、分發或發送。接收此類文件的人員（包括但不限於提名人、受託人和保管人）應遵守這些限制。未能遵守可能構成對任何此類司法管轄區證券法的違反。在適用法律允許的最大範圍內，Mural、XOMA Royalty 和 Sub 對任何人違反任何此類限制不承擔任何責任或義務。</p>
<p><strong>網站發佈</strong></p>
<p>根據愛爾蘭收購規則第 26.1 條，本公告的副本將在 Mural 的網站 https://ir.muraloncology.com/ 上發佈，最遲在本公告發布後的工作日中午 12:00（美國東部時間）之前。公告中提及的網站內容以及從該網站超鏈接訪問的任何其他網站的內容均不構成本公告的一部分。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU56UXdPQ00zTXpBM05qSXhJekl5TmpJek5ETT0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU56UXdPQ00zTXpBM05qSXhJekl5TmpJek5ETT0"/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2M0YTM0YTQtYTE2Ni00Y2ExLWIxZGItNTViNGJmNTZmMmY0LTEyNzM4OTMtMjAyNS0xMi0wNS1lbg==/tiny/Mural-Oncology-Inc-.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2M0YTM0YTQtYTE2Ni00Y2ExLWIxZGItNTViNGJmNTZmMmY0LTEyNzM4OTMtMjAyNS0xMi0wNS1lbg==/tiny/Mural-Oncology-Inc-.png"/></p>

MURA

<p>Mural Oncology plc 宣佈其安排計劃的有效性，這導致其被 XRA 5 Corp. 收購，後者是 XOMA Royalty Corporation 的子公司。此次收購涉及 Mural 的全部已發行股本。預計現金對價的分配將很快開始，並將在 2025 年 12 月 19 日之前完成。Mural 的股票已於 2025 年 12 月 4 日從納斯達克全球市場退市。前瞻性聲明提醒潛在的風險和不確定性</p>

<p>WALTHAM, Mass. and DUBLIN, Dec. 05, 2025 (GLOBE NEWSWIRE) -- Mural Oncology plc, (Nasdaq: MURA) (“ <strong>Mural</strong>”) announces that the scheme of arrangement between Mural and its shareholders under Chapter 1 of Part 9 of the Companies Act 2014 (the “ <strong>Scheme</strong>”) pursuant to which XRA 5 Corp. (“ <strong>Sub</strong>”), a wholly-owned subsidiary of XOMA Royalty Corporation (Nasdaq: XOMA) (“ <strong>XOMA Royalty</strong>”) will acquire the entire issued and to be issued share capital of Mural, became effective today, 5 December 2025 (the “ <strong>Effective Date</strong>”).</p>
<div class="lb-trans"><p>馬薩諸塞州沃爾瑟姆和都柏林，2025 年 12 月 5 日（全球新聞稿）—— Mural Oncology plc（納斯達克：MURA）（“ <strong>Mural</strong>”）宣佈，根據 2014 年公司法第 9 部分第 1 章的安排計劃（“ <strong>計劃</strong>”），XRA 5 Corp.（“ <strong>子公司</strong>”），XOMA Royalty Corporation（納斯達克：XOMA）（“ <strong>XOMA Royalty</strong>”）的全資子公司，將收購 Mural 的全部已發行和待發行股份，計劃於 2025 年 12 月 5 日（“ <strong>生效日期</strong>”）生效。</p>
</div><p>Distribution of cheques and crediting of DTC participant accounts for the cash consideration paid by Sub to Scheme Shareholders under the terms of the Scheme is expected to commence as soon as practicable following the Effective Date, with DTC participant accounts expected to be credited and the distribution of cheques expected to be complete as soon as practicable. In accordance with the requirements of the Irish Takeover Rules, all consideration paid by Sub to Scheme Shareholders under the terms of the Scheme will be distributed by no later than 19 December 2025.</p>
<div class="lb-trans"><p>根據計劃條款，子公司向計劃股東支付的現金對價的支票分發和 DTC 參與者賬户的記賬預計將在生效日期後儘快開始，DTC 參與者賬户預計將被記賬，支票分發預計將盡快完成。根據愛爾蘭收購規則的要求，子公司向計劃股東支付的所有對價將在 2025 年 12 月 19 日之前分發完畢。</p>
</div><p>Cancellation of the admission of Mural Shares to trading on the Nasdaq Global Market occurred with effect from 8.00 pm (U.S. Eastern Time) on 4 December 2025.</p>
<div class="lb-trans"><p>Mural 股份在納斯達克全球市場的交易取消自 2025 年 12 月 4 日美國東部時間晚上 8:00 起生效。</p>
</div><p>Except as otherwise defined herein, capitalised terms used but not defined in this announcement have the same meanings as given to them in the definitive proxy statement of Mural dated 23 September 2025 relating to the Acquisition, which also constitutes a scheme circular under Irish law.</p>
<div class="lb-trans"><p>除非另有定義，本公告中使用但未定義的專有名詞與 Mural 於 2025 年 9 月 23 日發佈的關於收購的最終代理聲明中所賦予的含義相同，該聲明也構成了根據愛爾蘭法律的計劃通函。</p>
</div><p>NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION</p>
<div class="lb-trans"><p>不得在任何法律或法規禁止的司法管轄區內全部或部分發布、出版或分發本公告。</p>
</div><p>FOR IMMEDIATE RELEASE</p>
<div class="lb-trans"><p>立即發佈</p>
</div><p><strong>Enquiries</strong></p>
<div class="lb-trans"><p><strong>諮詢</strong></p>
</div><p>Mural Oncology plc</p>
<div class="lb-trans"><p>Mural Oncology plc</p>
</div><p>ir@muraloncology.com</p>
<div class="lb-trans"><p>ir@muraloncology.com</p>
</div><p>Lucid Capital Markets, LLC (Financial Adviser to Mural)</p>
<div class="lb-trans"><p>Lucid Capital Markets, LLC（Mural 的財務顧問）</p>
</div><p>570 Lexington Ave, 40th Floor</p>
<div class="lb-trans"><p>570 Lexington Ave, 40 樓</p>
</div><p>New York, NY 10022</p>
<div class="lb-trans"><p>紐約，NY 10022</p>
</div><p><strong>Cautionary Note Regarding Forward-Looking Statements</strong></p>
<div class="lb-trans"><p><strong>關於前瞻性聲明的警示説明</strong></p>
</div><p>Statements contained in this announcement regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 with respect to Mural, XOMA Royalty or Sub. Forward-looking statements are intended to be identified by words such as “anticipate”, “target”, “expect”, “estimate”, “intend”, “plan”, “believe”, “will”, “may”, “would”, “could” or “should” or other words of similar meaning or the negative thereof. Forward-looking statements include but are not limited to statements regarding the expected timing of the payment of the consideration paid by Sub to Scheme Shareholders and the expected timing of the cancellation of the admission of Mural Shares to trading on the Nasdaq Global Market.</p>
<div class="lb-trans"><p>本公告中關於非歷史事實事項的聲明為 1995 年私人證券訴訟改革法案所定義的 “前瞻性聲明”，涉及 Mural、XOMA Royalty 或子公司。前瞻性聲明旨在通過 “預期”、“目標”、“期待”、“估計”、“打算”、“計劃”、“相信”、“將”、“可能”、“會”、“可以” 或 “應該” 或其他類似含義的詞語或其否定形式來識別。前瞻性聲明包括但不限於關於子公司向計劃股東支付對價的預計時間以及 Mural 股份在納斯達克全球市場交易取消的預計時間的聲明。</p>
</div><p>These forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the actual results to be materially different from those expressed or implied by such forward-looking statements. Risks and uncertainties that may cause actual results to differ from expectations include: risks and uncertainties pertaining to Mural’s business, including those described in Mural’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission (the “SEC”) and definitive proxy statement filed with the SEC on 23 September 2025, as well as Mural’s subsequent filings with the SEC; and other potential risks and uncertainties related to XOMA Royalty, including those described in more detail in XOMA Royalty’s most recent Annual Report on Form 10-K, Quarterly Report on Form 10-Q and its other filings with the SEC. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date when made. All subsequent oral or written forward-looking statements attributable to Mural, XOMA Royalty or Sub or any persons acting on their behalf are expressly qualified in their entirety by the cautionary statement above. None of Mural, XOMA Royalty or Sub undertake any obligation to update or revise the forward-looking statements contained in this announcement, whether as a result of new information, future events or otherwise, except to the extent legally required.</p>
<div class="lb-trans"><p>這些前瞻性聲明涉及已知和未知的風險、不確定性及其他因素，可能導致實際結果與這些前瞻性聲明所表達或暗示的結果存在重大差異。可能導致實際結果與預期不同的風險和不確定性包括：與 Mural 業務相關的風險和不確定性，包括在 Mural 最近提交的 10-K 表格年度報告、向美國證券交易委員會（“SEC”）提交的 10-Q 表格季度報告以及 2025 年 9 月 23 日向 SEC 提交的最終代理聲明中所描述的風險和不確定性，以及與 XOMA Royalty 相關的其他潛在風險和不確定性，包括在 XOMA Royalty 最近提交的 10-K 表格年度報告、10-Q 表格季度報告及其其他向 SEC 提交的文件中更詳細描述的風險和不確定性。您被警告不要對這些前瞻性聲明過於依賴，這些聲明僅在作出時有效。所有後續口頭或書面的前瞻性聲明，歸因於 Mural、XOMA Royalty 或子公司或其代表的任何人，均完全受上述警示聲明的限制。Mural、XOMA Royalty 或子公司均不承擔更新或修訂本公告中包含的前瞻性聲明的任何義務，無論是由於新信息、未來事件還是其他原因，除非法律要求。</p>
</div><p><strong>Statements Required by the Irish Takeover Rules</strong></p>
<div class="lb-trans"><p><strong>愛爾蘭收購規則要求的聲明</strong></p>
</div><p>The directors of Mural accept responsibility for the information contained in this announcement. To the best of the knowledge and belief of the directors of Mural (who have taken all reasonable care to ensure such is the case), the information contained in this announcement is in accordance with the facts and does not omit anything likely to affect the import of such information.</p>
<div class="lb-trans"><p>Mural 的董事會對本公告中包含的信息承擔責任。根據 Mural 董事會的最佳知識和信念（董事會已採取一切合理的注意以確保情況如此），本公告中包含的信息符合事實，並未遺漏任何可能影響該信息重要性的內容。</p>
</div><p>Lucid, which is authorized and regulated by the SEC and the Financial Industry Regulatory Authority (“ <strong>FINRA</strong>”) in the United States, is acting as financial adviser exclusively for Mural and for no one else in connection with the subject matter of this Announcement and will not regard any other person as its client in relation to the matters in this Announcement and will not be responsible to anyone other than Mural for providing the protections afforded to clients of Lucid or its affiliates, nor for providing advice in relation to any matter referred to in this Announcement. Neither Lucid nor any of its subsidiaries, affiliates or branches owes or accepts any duty, liability or responsibility whatsoever (whether direct, indirect, consequential, whether in contract, in tort, under statute or otherwise) to any person who is not a client of Lucid in relation to the matters in this Announcement, any statement or other matter or arrangement referred to herein or otherwise.</p>
<div class="lb-trans"><p>Lucid 在美國由 SEC 和金融業監管局（“ <strong>FINRA</strong>”）授權和監管，作為 Mural 的財務顧問，僅為 Mural 提供服務，而不為其他任何人提供與本公告主題相關的服務，並且不會將任何其他人視為其在本公告事項中的客户，也不會對除 Mural 以外的任何人提供 Lucid 或其附屬公司的客户所享有的保護，也不會就本公告中提到的任何事項提供建議。Lucid 及其任何子公司、附屬公司或分支機構對任何非 Lucid 客户在本公告中涉及的事項、任何聲明或其他事項或安排不承擔或接受任何責任（無論是直接、間接、後果性，無論是合同、侵權、法定或其他方式）。</p>
</div><p>Davy Corporate Finance, which is authorized and regulated in Ireland by the Central Bank of Ireland, is acting exclusively for XOMA Royalty and no one else in connection with the matters referred to in this Announcement and will not be responsible to anyone other than XOMA Royalty for providing the protections afforded to clients of Davy Corporate Finance or for providing advice in connection with the matters referred to in this Announcement.</p>
<div class="lb-trans"><p>Davy Corporate Finance 在愛爾蘭由愛爾蘭中央銀行授權和監管，專門為 XOMA Royalty 提供服務，與本公告中提及的事項相關，不對除 XOMA Royalty 以外的任何人負責提供 Davy Corporate Finance 客户所享有的保護或提供與本公告中提及的事項相關的建議。</p>
</div><p>Wilmer Cutler Pickering Hale and Dorr LLP and Arthur Cox LLP are acting as legal advisers on U.S. and Irish law matters respectively to Mural, and Gibson, Dunn &amp; Crutcher LLP and Mason Hayes &amp; Curran LLP are acting as legal advisers on U.S. and Irish law matters respectively to XOMA Royalty and Sub.</p>
<div class="lb-trans"><p>Wilmer Cutler Pickering Hale and Dorr LLP 和 Arthur Cox LLP 分別作為 Mural 的美國和愛爾蘭法律顧問，而 Gibson, Dunn &amp; Crutcher LLP 和 Mason Hayes &amp; Curran LLP 則分別作為 XOMA Royalty 和 Sub 的美國和愛爾蘭法律顧問。</p>
</div><p><strong>General</strong></p>
<div class="lb-trans"><p><strong>一般信息</strong></p>
</div><p>The release, publication or distribution of this announcement in or into certain jurisdictions may be restricted by the laws of those jurisdictions. Accordingly, copies of this announcement and all other documents relating to the Acquisition are not being, and must not be, released, published, mailed or otherwise forwarded, distributed or sent in, into or from any such restricted jurisdictions. Persons receiving such documents (including, without limitation, nominees, trustees and custodians) should observe these restrictions. Failure to do so may constitute a violation of the securities laws of any such jurisdiction. To the fullest extent permitted by applicable law, each of Mural, XOMA Royalty and Sub disclaims any responsibility or liability for the violations of any such restrictions by any person.</p>
<div class="lb-trans"><p>本公告的發佈、公佈或分發在某些司法管轄區可能受到該等司法管轄區法律的限制。因此，本公告及與收購相關的所有其他文件的副本不得在任何此類受限司法管轄區內或向其發佈、公佈、郵寄或以其他方式轉發、分發或發送。接收此類文件的人員（包括但不限於提名人、受託人和保管人）應遵守這些限制。未能遵守可能構成對任何此類司法管轄區證券法的違反。在適用法律允許的最大範圍內，Mural、XOMA Royalty 和 Sub 對任何人違反任何此類限制不承擔任何責任或義務。</p>
</div><p><strong>Publication on a Website</strong></p>
<div class="lb-trans"><p><strong>網站發佈</strong></p>
</div><p>In accordance with Rule 26.1 of the Irish Takeover Rules, a copy of this announcement will be available on Mural’s website at https://ir.muraloncology.com/ by no later than 12:00 noon (U.S. Eastern Time) on the business day following publication of this announcement. Neither the content of the website referred to in this announcement nor the content of any other websites accessible from hyperlinks on such website is incorporated into, or forms part of, this announcement.</p>
<div class="lb-trans"><p>根據愛爾蘭收購規則第 26.1 條，本公告的副本將在 Mural 的網站 https://ir.muraloncology.com/ 上發佈，最遲在本公告發布後的工作日中午 12:00（美國東部時間）之前。公告中提及的網站內容以及從該網站超鏈接訪問的任何其他網站的內容均不構成本公告的一部分。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.globenewswire.com/newsroom/ti/query-bmY9T1RVNU56UXdPQ00zTXpBM05qSXhJekl5TmpJek5ETT0" alt="" original-src="https://www.globenewswire.com/newsroom/ti?nf=OTU5NzQwOCM3MzA3NjIxIzIyNjIzNDM="/></p>
<p><img src="https://imageproxy.pbkrs.com/https://ml.globenewswire.com/media/M2M0YTM0YTQtYTE2Ni00Y2ExLWIxZGItNTViNGJmNTZmMmY0LTEyNzM4OTMtMjAyNS0xMi0wNS1lbg==/tiny/Mural-Oncology-Inc-.png" alt="" original-src="https://ml.globenewswire.com/media/M2M0YTM0YTQtYTE2Ni00Y2ExLWIxZGItNTViNGJmNTZmMmY0LTEyNzM4OTMtMjAyNS0xMi0wNS1lbg==/tiny/Mural-Oncology-Inc-.png"/></p>

Mural Oncology 宣佈安排計劃的生效及收購的完成 | MURA 股票新聞